



LABORATORY REPORT

NAME	: MR.PR0532	REFERRED BY	: SELF	VISIT NO	: VAMP26148138
AGE	: 40Y 0M 0D	ZERO TARIFF CLIENT CODE		COLLECTED ON	: 21-04-2026 10:00
GENDER	: Male	LAB MR#	: AAMP01479417	RECEIVED ON	: 21-04-2026 19:51
OP / IP / DG #	:			APPROVED ON	: 22-04-2026 18:03
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Ild Panel

BIOCHEMISTRY

Rheumatoid Factor (RA) - Quantitative - Serum (Serum)

Rheumatoid Factor (RA) - Quantitative - Serum <i>Immunoturbidimetry</i>	7.2	<14.0 (Negative)	IU/mL
--	-----	------------------	-------

C-Reactive Protein (CRP) -quantitative (Serum)

C-Reactive Protein (CRP) Quantitative <i>Immunoturbidimetry</i>	2.5	<5.0 (Negative)	mg/L
--	-----	-----------------	------

Anti Cyclic Citrullinated Peptide (Anti - CCP) (Serum)

Anti - CCP <i>ECLIA</i>	10.2	<=17.0	U/mL
----------------------------	------	--------	------

Interpretation:

- Cyclic Citrullinated Peptide test used for the semi-quantitative determination of the IgG class of auto antibodies specific to CCP in biological specimens.
- High levels seen in Rheumatoid Arthritis, and in other rheumatologic conditions associated with inflammatory arthritis, such as systemic lupus erythematosus
- Low levels may be seen in low disease activity or patients in remission diagnosed with Rheumatoid Arthritis

Note:

- Anti CCP is present in only a quarter to half of patients before or at diagnosis, so a negative result does not rule out Rheumatoid Arthritis
- Patients on Biotin supplement may have interference in some immunoassays. With individuals taking high dose Biotin (more than 5 mg per day) supplements, at least 8-hour wait time before blood draw is recommended.
- The above results obtained cannot be compared to or interchanged with results determined by different assays due to differences in assay methods and reagent specificity.

Angiotensin Converting Enzyme (ACE) - Serum (Serum)

ACE <i>Enzymatic</i>	45.00	12-68	U/L
-------------------------	-------	-------	-----

Interpretation:

Angiotensin converting enzyme (ACE) modulates peripheral vascular resistance as well as renal and cardiovascular function. It is responsible for conversion of Angiotensin I to Angiotensin II as well as inactivation of bradykinin. Majority of ACE is tissue bound (> 90%) found predominantly in lungs & testes.

Factors affecting ACE levels: ·

- Smoking - ACE activity is 30% lower in smokers
- Thyroid hormone- Stimulates ACE synthesis



AMPATH
Central Reference Labor
Door No. 1-100/1/CCH N
Serilingampally
Hyderabad



LABORATORY REPORT

NAME	: MR.PR0532	REFERRED BY	: SELF	VISIT NO	: VAMP26148138
AGE	: 40Y 0M 0D	ZERO TARIFF CLIENT CODE		COLLECTED ON	: 21-04-2026 10:00
GENDER	: Male	LAB MR#	: AAMP01479417	RECEIVED ON	: 21-04-2026 19:51
OP / IP / DG #	:			APPROVED ON	: 22-04-2026 18:03
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Ild Panel

Postmenopausal estrogen replacement - ACE activity is 20% lower

Patients taking ACE inhibitors, such as captopril and enalapril, will have extremely low or unmeasurable ACE activity.

Generated On 25-Apr-2026 11:03:15

This is an electronically authenticated laboratory report.

Page 2 of 7

Sin No: 20385435





MC-2751

LABORATORY REPORT

NAME : MR.PR0532	REFERRED BY : SELF	VISIT NO : VAMP26148138
AGE : 40Y 0M 0D	ZERO TARIFF CLIENT CODE	COLLECTED ON : 21-04-2026 10:00
GENDER : Male	LAB MR# : AAMP01479417	RECEIVED ON : 21-04-2026 18:11
OP / IP / DG # :		APPROVED ON : 22-04-2026 12:58
		REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Iid Panel

SEROLOGY AND IMMUNOLOGY

Anti Nuclear Antibody (ANA) - IFA - Pattern identification on Hep-2 cells with reflex titers (Serum)

ANA Hep-2 Negative Negative
Immuno fluorescence Microscopy

Interpretation:

ANALYTICAL INFERENCE DRAWN FROM FLUORESCENCE ON: HEP-2 Cells
ADVICE/COMMENT: Correlate clinically.

Interpretation:

ANA reactivity	Interpretation
No Fluorescence at 1:80	Negative. (No antibodies against cell nuclei detectable in the given sample).
Fluorescence at 1:80	Positive

The titre is derived from inverse ratio of dilution factor for which specific fluorescence is identifiable. Immunofluorescent pattern detection of Anti-nuclear antibodies in human serum for the diagnosis of various related auto-immune disorders is facilitated through the use of artificially cultured HEP-2 cells as micro-chips on slides. Various nuclear / cytoplasmic patterns of fluorescence obtained on incubation with diluted patient serum give an idea of the prevalence of relevant auto-antibodies in that patient, which can thereafter be semi-quantified by testing serial dilutions of the serum. The end-point titre is considered to be the highest dilution to still give a positive result. The significance of titre depends to some extent on the age of the patient, as auto-antibodies are more frequent in the elderly. Titres of 1:40 are of limited importance for patients over 50 years of age. The antibody titres may help to track disease progression and therapeutic responses. ANA patterns are only indicative, and the specificity of the auto-antibody must always be confirmed by other techniques such as immunoblotting, ELISA etc.

Location	Pattern	Target Antigen	Clinical Association		
Nucleus	Homogeneous	Double strand DNA	SLE		
		Histones	Drug Induced Lupus, SLE , RA		
		Nucleosome, RNA, Single Strand DNA	SLE, MCTD, RA, PM, DM, SS		
		Sm	SLE		
		U1-snRNP	MCTD, SLE, RA, sharp syndrome		
Speckled/Granular	Speckled/Granular	SSA/Ro	Sjogren's syndromes		
		SSB/La	(SS)/SLE/Neonatal Lupus		
		Ku	PM/DM/SLE/SS		
		Cyclin1(PCNA)	SLE/Overlap Syndromes		
		Mitosis/Cyclin II	DM		
		Dense Fine Speckled(DFS)	Dense Fine Speckled(DFS)	Lens epithelium-derived growth factor (LEDGF), DNA binding transcription coactivator p75.(DFS-70)	Healthy individuals, Various Inflammatory conditions like atopic dermatitis, interstitial cystitis, Asthma.
				Centomeres	CREST syndrome, PSS limited form
Nuclear Dots	Sp-100 , NDP53				
Nucleolus	Nucleolar homogeneous	Lamins, gp210, p62	CFS, Collagenoses, PBC, AIH		
		PM-Scl	PM, DM, PSS(Diffuse)		
		Scl-70	PSS(Diffuse)		

Generated On 25-Apr-2026 11:03:15

This is an electronically authenticated laboratory report.

Page 3 of 7



Sin No: 20385435



LABORATORY REPORT

NAME : MR.PR0532	REFERRED BY : SELF	VISIT NO : VAMP26148138
AGE : 40Y 0M 0D	ZERO TARIFF CLIENT CODE	COLLECTED ON : 21-04-2026 10:00
GENDER : Male	LAB MR# : AAMP01479417	RECEIVED ON : 21-04-2026 18:11
OP / IP / DG # :		APPROVED ON : 22-04-2026 12:58
		REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
Iid Panel			
CENP B	Negative	Negative	
Scl-70	Negative	Negative	
nRNP/Sm	Negative	Negative	
AMA-M2(M2)	Negative	Negative	
Jo-1	Negative	Negative	
PM - SCL (PM)	Negative	Negative	
Mi-2	Negative	Negative	
Ku	Negative	Negative	

Interpretation:

Antigen	Disease	Prevalance of autoantibodies
nRNP/Sm	MCTD	95-100%
	SLE	15-40%
	SS	2-12%
	PM/DM	12-16%
Sm (Smith antigen)	SLE	5-40%
SS-A (Ro)	SS	40-95%
	SLE	22-60%
	Neonatal lupus	95-100%
Ro-52	SS or SLE	40-95%, 40-60%
SS-B (La)	SS	40-95%
	SLE	10-20%
	Neonatal lupus	75%
Scl-70	SS	25-75%
Pm-Scl	SS	10-20%
	PM-SS Overlap synd	18%
Jo-1	PM/DM	25-35%
Centromeres	SS limited form	80-95%
	SS diffuse form	8%
	PBC	10-30%
dsDNA	SLE	40-90%
Nucleosomes	SLE	40-70%





LABORATORY REPORT

NAME : MR.PR0532	REFERRED BY : SELF	VISIT NO : VAMP26148138
AGE : 40Y 0M 0D	ZERO TARIFF CLIENT CODE	COLLECTED ON : 21-04-2026 10:00
GENDER : Male	LAB MR# : AAMP01479417	RECEIVED ON : 21-04-2026 18:11
OP / IP / DG # :		APPROVED ON : 22-04-2026 12:58
		REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
Iid Panel			
Histones	DLE	95-100%	
	SLE	50%	
	RA	15-50%	
Ribosomes P-protein	SLE	10%	
AMA-M2	PBC	96%	

NOTE:

- Sample screening dilution - 1:101
- Immunoblot assay detects selected 14 ANAs which are most important & clinically relevant. However, in general, ANA includes many autoantibodies directed towards many nuclear (DNA & nucleoplasm) & cytoplasmic antigens, which are maximally screened & detected by using Hep-2 cells in indirect immunofluorescence method, but, not all of these are always clinically relevant antibodies.
- There is a possibility of patients having ANA positive by indirect immunofluorescence method but negative results on immunoblot. Also note that Immunoblot assay is more sensitive for Ro52/SSa, Scl70, while poorly sensitive for DsDNA, hence such patients require further follow up with monospecific ELISAs based on clinical correlation & diagnosis.
- For weak Positive results repeat testing after 4-6 weeks or further testing with Monospecific Nuclear Antigens or Panels for confirmation of specific Autoantibodies is suggested.

Anti-MPO Antibodies (Anti-Myleoperoxidase Antibodies) - pANCA (Serum)

Anti-MPO Antibodies - p- ANCA ELISA	6.30	Negative: ≤ 20 Weak Positive: 21-30 Positive: >30	UNITS
--	------	---	-------

Interpretation:

MPO- EIA test is recommended to confirm Anti MPO specificity because true ANA as well as granulocyte specific ANA are known to occur concurrently & Immunofluorescence methods may not adequately make this distinction . Hence a combination of Immunofluorescence & EIA methods are recommended for confirming presence of MPO antibody / p-ANCA. Anti MPO antibodies are highly specific for idiopathic and vasculitis associated Crescentic Glomerulonephritis, Classic Polyarteritis Nodosa, Churg-Strauss Syndrome and polyangitis overlap syndrome without renal involvement.

Anti-PR3 Antibodies - cANCA (Serum)

Anti-PR3 Antibodies - cANCA ELISA	8.20	Negative: ≤ 20 Weak Positive: 21-30	Units
--------------------------------------	------	--	-------

Generated On 25-Apr-2026 11:03:15

This is an electronically authenticated laboratory report.

Page 6 of 7



Sin No: 20385435



LABORATORY REPORT

NAME	: MR.PR0532	REFERRED BY	: SELF	VISIT NO	: VAMP26148138
AGE	: 40Y 0M 0D	ZERO TARIFF CLIENT CODE		COLLECTED ON	: 21-04-2026 10:00
GENDER	: Male	LAB MR#	: AAMP01479417	RECEIVED ON	: 21-04-2026 18:11
OP / IP / DG #	:			APPROVED ON	: 22-04-2026 12:58
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Ild Panel

Positive: >30

Interpretation:

Presence of c-ANCA antibodies in patients with Small vessel vasculitis strongly suggests the diagnosis of Wegener's granulomatosis in 95% of cases in the active generalized stage of the disease but a negative test result does not exclude the possibility of these disorders. c-ANCA disappears in majority of patients when treated with corticosteroids, cyclophosphamides or plasma exchange therapy. Reappearance of antibodies in these patients indicates recurrence. Results should be used in conjunction with clinical findings and other serological tests including ANCA by indirect immunofluorescence.

Dr. Sanjeeta
MBBS,MD (Biochemistry)
Consultant Biochemist

Dr. G. Amitha
MBBS, MD (MICROBIOLOGY)
Consultant Microbiologist

Disclaimer:

1. All results released pertain to the specimen as received by the lab for testing and under the assumption that the patient indicated or identified on the bill/test requisition form is the owner of the specimen.
2. Clinical details and consent forms, especially in Genetic testing, histopathology, as well as wherever applicable, are mandatory to be accompanied with the test requisition form. The non-availability of such information may lead to delay in reporting as well as misinterpretation of test results. The lab will not be responsible for any such delays or misinterpretations thereof.
3. Test results are dependent on the quality of the sample received by the lab. In case the samples are preprocessed elsewhere (e.g., paraffin blocks), results may be compromised.
4. Tests are performed as per the schedule given in the test listing and in any unforeseen circumstances, report delivery may be affected.
5. Test results may show inter-laboratory as well as intra-laboratory variations as per the acceptable norms.
6. Genetic reports as well as reports of other tests should be correlated with clinical details and other available test reports by a qualified medical practitioner. Genetic counselling is advised in genetic test reports by a qualified genetic counsellor, medical practitioner or both.
7. Samples will be discarded post processing after a specified period as per the laboratory's retention policy. Kindly get in touch with the lab for more information.
8. If accidental damage, loss, or destruction of the specimen is not attributable to any direct or negligent act or omission on the part of Ampath Labs or its employees, Ampath shall in no event be liable. Ampath lab's liability for a lack of services, or other mistakes and omissions, shall be restricted to the amount of the patient's payment for the pertinent laboratory services.

